BioMarin
Develops rare-disease medicines across enzyme therapies, metabolic disorders, and skeletal conditions.
Something off on this page? Send us feedback.
Profile
Develops therapies for serious rare genetic diseases across enzyme replacement, metabolic disorders, and skeletal conditions. Revenue comes from a commercial portfolio led by VOXZOGO and long-standing enzyme therapies, now expanded with GALAFOLD and POMBILITI + OPFOLDA; operations remain a single reportable segment.
Develops and commercializes therapies for serious rare genetic diseases, with one operating segment spanning enzyme and metabolic medicines plus skeletal conditions. The commercial portfolio includes the long-standing enzyme therapies VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, and BRINEURA, the PKU medicine KUVAN, and VOXZOGO for achondroplasia.
Extends that base with GALAFOLD for Fabry disease and POMBILITI + OPFOLDA for late-onset Pompe disease, acquired with Amicus Therapeutics. Internal research, biologics manufacturing, and commercial capabilities support treatment of genetically defined conditions with small patient populations.
Commercializes therapies across multiple markets, while each medicine depends on regulatory approvals, reliable manufacturing, patient identification, and reimbursement. Continued execution also depends on integrating the Amicus portfolio and extending the skeletal-conditions franchise after withdrawing ROCTAVIAN from the market.
Company facts
Key statistics
Year to date +8.7% · Average volume (30d) 2.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 26, 2026 | UBS | Target | $114 | $88 | |
| Aug 18, 2026 | BMO Capital | Initiate | Outperform | $115 | $98 |
| Aug 18, 2026 | H.C. Wainwright | Target | $50 | $59 | |
| Aug 17, 2026 | Piper Sandler | Reiterate | Overweight | $84 | $88 |
| Aug 17, 2026 | Barclays | Reiterate | Overweight | $105 | $111 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $0.95 | $1.20 | +26.7% | $932.0M | $989.7M | +6.2% | +3.82% |
| May 4, 2026Q1 FY26 | $0.94 | $0.76 | −19.1% | $752.5M | $766.0M | +1.8% | −4.00% |
| Feb 23, 2026Q4 FY25 | $0.17 | −$0.24 | −241.7% | $833.7M | $874.6M | +4.9% | −0.48% |
| Oct 27, 2025Q3 FY25 | −$0.15 | $0.12 | +180.0% | $823.5M | $776.1M | −5.7% | +1.56% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $745.1M | $825.4M | $776.1M | $874.6M | $766.2M | $989.7M | |
| Gross profit | $593.6M | $675.3M | $636.0M | $579.5M | $571.2M | $786.9M | |
| Operating income | $223.9M | $276.9M | −$46.7M | $79.4M | $129.6M | $110.9M | |
| Net income | $185.7M | $240.5M | −$30.7M | −$46.6M | $105.5M | $44.8M | |
| Diluted EPS | $0.95 | $1.23 | −$0.16 | −$0.22 | $0.54 | $0.23 | |
| Gross margin | 79.7% | 81.8% | 82.0% | 66.3% | 74.6% | 79.5% | |
| Operating margin | 30.0% | 33.5% | -6.0% | 9.1% | 16.9% | 11.2% |
Fiscal years (4-quarter sums)FY21 $1.85B · FY22 $2.10B · FY23 $2.42B · FY24 $2.85B · FY25 $3.22B
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $874.0M · Total debt $4.20B · Total assets $11.72B · Shareholders' equity $6.32B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 193.28M · Float 192.09M · 99.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 20.45M | 10.58% | 13F | Aug 7, 2026 |
| Dodge & Cox | 14.84M | 7.68% | 13F | Aug 13, 2026 |
| Primecap Management Co/CA/ | 14.19M | 7.34% | 13F | Aug 14, 2026 |
| Vanguard Capital Management LLC | 8.74M | 4.52% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 8.65M | 4.47% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 7, 2026 | Gregory R. Friberg | officer: EVP, Chief R&D Officer | −3,281 | $53.85 |
| Mar 11, 2026 | Charles Greg Guyer | officer: EVP, Chief Technical Officer | −16,486 | $60.46 |
| Feb 26, 2026 | George Eric Davis | officer: EVP, Chief Legal Officer | −26,061 | $61.36 |
| Feb 26, 2026 | Gregory R. Friberg | officer: EVP, Chief R&D Officer | −6,326 | $60.38 |
Peers
- Ascendis Pharma (ADR)
Once-weekly CNP rival to VOXZOGO in achondroplasia
- Sanofi (ADR)
Direct Fabry and Pompe rival through Fabrazyme and Nexviazyme
- PTC Therapeutics
Commercial PKU rival to KUVAN and PALYNZIQ
- BridgeBio Pharma
Oral FGFR3 inhibitor challenging VOXZOGO in achondroplasia
- Protalix BioTherapeutics
Fabry enzyme-replacement rival to GALAFOLD
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioMarin | $64.67 | +0.02% | $12.50B | 165.8 | 10.4 | 3.7 | +19.9% |
| Ascendis Pharma (ADR) | $247.91 | 0.00% | $15.40B | 18.7 | 31.9 | 12.6 | +108.2% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| PTC Therapeutics | $70.59 | +0.73% | $5.85B | — | 58.0 | 5.8 | +101.6% |
| BridgeBio Pharma | $76.60 | +0.03% | $15.00B | — | — | 21.7 | +120.4% |
| Protalix BioTherapeutics | $2.58 | +1.87% | $204.7M | 11.0 | — | 2.5 | +27.1% |
| Median | 18.7 | 45.0 | 5.8 | +101.6% |